News | News By Subject | News by Disease News By Date | Search News

Sarcoma News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
CytRx (CYTR) Plans to File NDA for Once-Failed Sarcoma Drug While Columnist Raises Questions Over Efficacy and CEO Salary Amid Struggle     11/30/2016
FDA Hits Adaptimmune (ADAP) with a Partial Hold on Pivotal Sarcoma Trial, Stock Tanks     8/4/2016
CytRx (CYTR) Craters After Aldoxorubicin Flops in Phase III Trial     7/12/2016
3 Biotechs Getting Another Shot After Failed Trials     4/7/2016
GlaxoSmithKline (GSK) Kills U.S. Part of Eczema Treatment Deal With Basilea (BSLN.SW)     1/22/2016
Threshold Pharma (THLD) Crumbles as Merck KGaA (MKGAF.PK) Abandons Cancer Drug After Trial Failures     12/7/2015
EXCLUSIVE: Navidea (NAVB) CEO Tells BioSpace (DHX) New Cancer Treatment Will See More Trial Data in 2015     4/29/2015
FDA Removes Partial Clinical Hold on CytRx Corporation (CYTR)'s Brain Cancer Trials     1/21/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
FDA Puts Partial Hold On CytRx Corporation (CYTR)'s Aldoxorubicin Clinical Trials     11/19/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
SSF's Threshold Pharmaceuticals, Inc. (THLD) Snags Fast Track Status For Experimental Cancer Drug TH-302     11/11/2014
CytRx Corporation (CYTR) Soars As Cancer Drug Meets Main Goal In Phase 2 Study     12/12/2013
ZIOPHARM Oncology, Inc. (ZIOP.OB)'s Treatment for Soft Tissue Sarcoma Meets Study Goals     2/12/2013
Eisai Company, Ltd. (ESALY.PK)'s Farletuzumab Fails Ovarian Cancer Trial     1/15/2013

News from Around the Web

Press Releases
Epizyme (EPZM) Announces Tazemetostat Granted Orphan Drug Designation For The Treatment Of Soft Tissue Sarcoma     6/21/2017
CytRx (CYTR) Announces Update On The Regulatory Pathway For Aldoxorubicin In Soft Tissue Sarcomas     6/8/2017
Adaptimmune (ADAP) Announces An Oral Presentation On Data From NY-ESO Study In Synovial Sarcoma And Four Trials In Progress Posters At The ASCO Annual Meeting     6/5/2017
CytRx (CYTR) Announces FDA Agreement On Regulatory Pathway To Approval For Aldoxorubicin In Soft Tissue Sarcomas     4/19/2017
TRACON Pharma (TCON) Announces First Patient Dosed In Phase III TAPPAS Trial Of TRC105 In Angiosarcoma     2/16/2017
CytRx (CYTR) Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas     1/4/2017
TRACON Pharma (TCON) Receives Special Protocol Assessment (SPA) Agreement From FDA For Phase III Clinical Trial Of TRC105 In Angiosarcoma     1/3/2017
Oxford Gene Technology Ltd. Expands Cytocell Sarcoma FISH Probe Range     12/15/2016
CytRx (CYTR) Reports Statistically Significant Updated Results From Pivotal Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcomas     11/29/2016
Arog Pharmaceuticals Receives Orphan Drug Designation In The European Union For Crenolanib For The Treatment Of Acute Myeloid Leukemia And Soft Tissue Sarcoma     11/22/2016
CytRx (CYTR) Presents Positive Interim Results From On-Going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting     11/14/2016
TRACON Pharma (TCON) Announces Presentation Of Updated Data From Phase Ib/II Study Of TRC105 And Votrient In Patients With Angiosarcoma     11/11/2016
Philogen S.p.A. Receives Orphan Drug Designation For The Treatment Of Soft Tissue Sarcoma     10/28/2016
FDA Approves Eli Lilly (LLY)'s LARTRUVO (Olaratumab) In Combination With Doxorubicin For Soft Tissue Sarcoma     10/20/2016
CytRx (CYTR) Presents Interim Results From On-Going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress     10/10/2016